VivoSeq
Other

Muscle Weakness

11

Pipeline Programs↗

5

Active Trials↗

8

Companies Involved↗

Muscle weakness is an emerging landscape with 11 programs across 8 companies. The most active players are Eli Lilly, Eisai, Viatris Specialty LLC. 2 therapies are approved with 3 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

40/100

Pipeline Velocity

15/100

Mech. Concentration

14/100

Completion Rate

80/100

Attrition Rate

9/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Eli Lilly logo

Eli Lilly

1 program

Phase 2Eisai logo

Eisai

1 program

Phase 2V

Viatris Specialty LLC

1 program

Phase 3S

Sinew Pharma Inc.

1 program

Phase 3A

Auxilium

1 program

ApprovedL

Leadiant Biosciences, Inc.

1 program

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

11

clinical trials

Completed4 · 36%
Active, not recruiting2 · 18%
Not yet recruiting2 · 18%
Terminated1 · 9%
Unknown status1 · 9%
Recruiting1 · 9%

Clinical Trials

Trial Activity

11 trials

Toward Ubiquitous Lower Limb Exoskeleton Use in Children and Young Adults: Exploratory Observational Analysis of Novel Robotic Control Strategies
Recruiting·National Institutes of Health Clinical Center (CC)·N/A·NCT06998134·23 enrolled
Safety and Efficacy of IMM01-STEM Against Placebo on Muscle Performance in Seniors With Obesity and Muscle Weakness
Active, not recruiting·IImmunis, Inc.·Phase 2·NCT06600581·55 enrolled
Rehabilitation, NMES and High Protein to Reduce Post ICU Syndrome in the Elderly
Active, not recruiting·UUniversity of Maryland, Baltimore·Preclinical·NCT02509520·60 enrolled
Progressive Pressure Support Reduction as Inspiratory Muscle Endurance Training in Mechanically Ventilated Critically Ill Patients: Effect on Maximal Inspiratory Pressure, Diaphragm Thickening Fraction, Weaning Success and Extubation (INSPIRA-RCT)
Not yet recruiting·UUniversity of Santiago de Compostela·Preclinical·NCT07689110·60 enrolled
Muscle Aging Phenotypes in Childhood Cancer Survivors
Not yet recruiting·SSt. Jude Children's Research Hospital·N/A·NCT07531498·533 enrolled
Transmucular Quadratus Lumborum Block: Potential Quadriceps Muscle Weakness
Completed·ZZealand University Hospital·Phase 4·NCT05023343·20 enrolled
The Effect of Anesthesia on Perioperative Muscle Weakness and Neuro-endocrine Stress Response
Completed·—·N/A·NCT03600454·50 enrolled
A Study in Older Participants Who Have Fallen and Have Muscle Weakness
Completed·Eli Lilly logoEli Lilly·Phase 2·NCT01604408·201 enrolled
Muscle Weakness Duration After Single Botulinum Toxin Injection in Masseter
Completed·—·N/A·NCT05309564·32 enrolled
Evaluating Muscle Weakness Improvement With Lorcaserin in ICU
Terminated·JJohns Hopkins University·Phase 1/2·NCT02523690·5 enrolled
Does Gabapentin Reduce Quadriceps Muscle Weakness After Anterior Cruciate Ligament Reconstruction?
Unknown status·HHospital Authority, Hong Kong·Phase 2/3·NCT03496389·30 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)